新股消息 | IFR:京東健康香港上市申請獲批,計劃下週開始路演
IFR未說明消息來源報道稱,京東健康30億美元IPO週四獲得香港交易所批準。
計劃下週開始上市前推介。
京東健康已於9月27日遞交香港上市申請表,初步招股書顯示,美銀、海通國際、UBS爲聯席保薦人。
根據弗若斯特沙利文的報告,按2019年收入計,京東健康是中國最大的在線醫療健康平臺及最大的在線零售藥房。
截至2020年6月30日,共逾1.5億名用戶曾使用京東健康的平臺購買醫藥和健康產品或醫療健康服務。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.